Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Cited In for PubMed (Select 19945742)

1.

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Zhang Y, Qiao C, Li L, Zhao X, Li Y.

Afr Health Sci. 2014 Dec;14(4):913-8. doi: 10.4314/ahs.v14i4.20.

2.

Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer.

Jiang Y, Wang C, Lv B, Ma G, Wang L.

Int J Clin Exp Med. 2014 Dec 15;7(12):5568-72. eCollection 2014.

3.

Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses.

Farzaneh F, Honarvar Z, Yaraghi M, Yaseri M, Arab M, Hosseini M, Ashrafgangoi T.

Iran Red Crescent Med J. 2014 Jun;16(6):e17185. doi: 10.5812/ircmj.17185. Epub 2014 Jun 5.

4.

Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

Zhen S, Bian LH, Chang LL, Gao X.

Mol Clin Oncol. 2014 Jul;2(4):559-566. Epub 2014 Apr 16.

5.

Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample.

Brain KE, Smits S, Simon AE, Forbes LJ, Roberts C, Robbé IJ, Steward J, White C, Neal RD, Hanson J; ICBP Module 2 Working Group.

BMC Cancer. 2014 Mar 10;14:171. doi: 10.1186/1471-2407-14-171.

6.

Value of symptom-triggered diagnostic evaluation for ovarian cancer.

Andersen MR, Lowe KA, Goff BA.

Obstet Gynecol. 2014 Jan;123(1):73-9. doi: 10.1097/AOG.0000000000000051.

7.

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.

Pitta Dda R, Sarian LO, Barreta A, Campos EA, Andrade LL, Fachini AM, Campbell LM, Derchain S.

BMC Cancer. 2013 Sep 18;13:423. doi: 10.1186/1471-2407-13-423.

8.

Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer.

Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z, Li L.

Oncol Lett. 2013 Jul;6(1):28-34. Epub 2013 May 8.

9.

The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Simmons AR, Baggerly K, Bast RC Jr.

Oncology (Williston Park). 2013 Jun;27(6):548-56. Review.

10.

Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.

Yang Z, Wei C, Luo Z, Li L.

Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Print 2013. Erratum in: Onco Targets Ther. 2014;7:135.

11.

The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.

Lawicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M.

J Ovarian Res. 2013 Jul 2;6(1):45. doi: 10.1186/1757-2215-6-45.

12.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

13.

Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616. Epub 2012 Sep 7.

14.

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer.

Kalapotharakos G, Asciutto C, Henic E, Casslén B, Borgfeldt C.

J Ovarian Res. 2012 Aug 21;5(1):20. doi: 10.1186/1757-2215-5-20.

15.

Diagnosis and management of peritoneal metastases from ovarian cancer.

Halkia E, Spiliotis J, Sugarbaker P.

Gastroenterol Res Pract. 2012;2012:541842. doi: 10.1155/2012/541842. Epub 2012 Jul 19.

16.

HE4, CA-125, and cystic ovarian mass.

Wiwanitkit V.

J Gynecol Oncol. 2012 Apr;23(2):133. doi: 10.3802/jgo.2012.23.2.133A. Epub 2012 Apr 3. No abstract available.

18.

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.

Partheen K, Kristjansdottir B, Sundfeldt K.

J Gynecol Oncol. 2011 Dec;22(4):244-52. doi: 10.3802/jgo.2011.22.4.244. Epub 2011 Dec 5.

19.

Designing early detection programs for ovarian cancer.

Urban N.

Ann Oncol. 2011 Dec;22 Suppl 8:viii6-viii18. doi: 10.1093/annonc/mdr472.

20.

Protein biomarkers of ovarian cancer: the forest and the trees.

Nolen BM, Lokshin AE.

Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk